Canada markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.18000.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

    Presentations to highlight continued progress toward initiation of human clinical trials with novel DNA-damage response inhibitorsVANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce two upcoming conference presentations. The 34th EORTC-NCI-AACR Molecular Targets and Cancer Therape

  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended June 30, 2022 and provided a corporate update. “We are pleased with the continued progress during this past quarter”, said Mr. Jeffrey Bacha executive chairman of Rakovina Therapeutics, Inc. “Our lead optimiz

  • GlobeNewswire

    Rakovina Therapeutics Announces Results from Annual General Meeting

    VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2022 Annual General Meeting of Shareholders held on June 23, 2022 (the “Meeting”). All four members of the Company’s Board of Directors named as nominees in its management information circular (the “Circular”